AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34382318 — intervention group
Group type: EXPERIMENTAL
Intervention: Shanley Pressure Ulcer Prevention Programme (SPUPP) - a multimedia programme delivered over 5 weeks with 5 sessions using electronic media, hard copy materials, activities, and patient diaries.
Number of subjects: 64
Study 34382318 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 64
Study 34382318 — intervention group
Group type: EXPERIMENTAL
Intervention: Shanley Pressure Ulcer Prevention Programme (SPUPP) - a multimedia programme delivered over 5 weeks.
Number of subjects: 64
Study 32078484 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol <70 mg/dL
Number of subjects: 1073
Study 32078484 — intervention group
Group type: COMPARATOR
Intervention: LDL cholesterol 100±10 mg/dL (90-110 mg/dL)
Number of subjects: 1073
Study 34907783 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute cycling bout in normoxia
Number of subjects: 32
Study 34907783 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute cycling bout in hypoxia
Number of subjects: 32
Study 34907783 — intervention group
Group type: COMPARATOR
Intervention: Control group (prediabetic subjects)
Number of subjects: 32
Study 33799037 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapy
Number of subjects: 0
Study 33799037 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning cortisol
Number of subjects: 0
Study 32767902 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile learning approach (test taken free of local or temporal fixations)
Number of subjects: 0
Study 32767902 — intervention group
Group type: COMPARATOR
Intervention: Traditional testing conditions (test taken at the local testing center)
Number of subjects: 0
Study 36376167 — intervention group
Group type: EXPERIMENTAL
Intervention: uMGMT/CAP (arm A)
Number of subjects: 60
Study 36376167 — intervention group
Group type: EXPERIMENTAL
Intervention: uMGMT/TMZ + CAP (arm B)
Number of subjects: 60
Study 36376167 — intervention group
Group type: EXPERIMENTAL
Intervention: mMGMT/CAP (arm C)
Number of subjects: 60
Study 36376167 — intervention group
Group type: EXPERIMENTAL
Intervention: mMGMT/TMZ + CAP (arm D)
Number of subjects: 60
Study 36376167 — intervention group
Group type: COMPARATOR
Intervention: CAP group (arms A + C)
Number of subjects: 60
Study 36376167 — intervention group
Group type: COMPARATOR
Intervention: TMZ + CAP group (arms B + D)
Number of subjects: 60
Study 36376167 — intervention group
Group type: COMPARATOR
Intervention: uMGMT group (arms A + B)
Number of subjects: 60
Study 36376167 — intervention group
Group type: COMPARATOR
Intervention: mMGMT group (arms C + D)
Number of subjects: 60
Study 34288017 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome of further bleeding within 30 days after randomisation leading to red blood cell transfusion, urgent intervention (repeat endoscopy; interventional radiology or surgery), or death
Number of subjects: 0
Study 34288017 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual components of the primary outcome
Number of subjects: 0
Study 32933153 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill Oil (KO) 1.27 g/day of long-chain omega-3 PUFA (0.76 g EPA, 0.42 g DHA)
Number of subjects: 11
Study 32933153 — intervention group
Group type: COMPARATOR
Intervention: Fish Oil (FO) 1.44 g/day of long-chain omega-3 PUFA (0.79 g EPA, 0.47 g DHA)
Number of subjects: 11
Study 35932394 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention targeting financial distress and tobacco use (financial coaching and social services referrals)
Number of subjects: 410
Study 35932394 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard smoking cessation treatment)
Number of subjects: 410
Study 34391302 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland's mobilization
Number of subjects: 40
Study 34391302 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization
Number of subjects: 40
Study 33890883 — intervention group
Group type: EXPERIMENTAL
Intervention: Active filtration system (Revolve; LifeCell Corporation)
Number of subjects: 46
Study 33890883 — intervention group
Group type: COMPARATOR
Intervention: Passive filtration system (PureGraft 250; Cytori Therapeutics)
Number of subjects: 46
Study 33890883 — intervention group
Group type: COMPARATOR
Intervention: Centrifugation
Number of subjects: 46
Study 32202943 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute PASI ≤ 2, N = 548
Number of subjects: 1054
Study 32202943 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% improvement in PASI, N = 559
Number of subjects: 1054
Study 32202943 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute PASI and PASI response
Number of subjects: 1054
Study 36442806 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump Start+: COVID 19 Support (JS + CS) virtual toolkit delivered via Kubi robot
Number of subjects: 0
Study 36442806 — intervention group
Group type: COMPARATOR
Intervention: Obesity prevention intervention (control group)
Number of subjects: 0
Study 34560858 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Based Intervention (HEBI)
Number of subjects: 0
Study 34560858 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35439608 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg once daily
Number of subjects: 0
Study 35439608 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg once daily
Number of subjects: 0
Study 33279353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Number of subjects: 124
Study 33279353 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 124
Study 33588669 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital care management
Number of subjects: 0
Study 32305424 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA)
Number of subjects: 5554
Study 32305424 — intervention group
Group type: COMPARATOR
Intervention: Steroids
Number of subjects: 5554
Study 32305424 — intervention group
Group type: COMPARATOR
Intervention: Single Platelet-Rich Plasma (PRP)
Number of subjects: 5554
Study 32305424 — intervention group
Group type: COMPARATOR
Intervention: Multiple PRP
Number of subjects: 5554
Study 32305424 — intervention group
Group type: COMPARATOR
Intervention: Adipose Mesenchymal Stromal Cells (MSC)
Number of subjects: 5554
Study 32305424 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 5554
Study 36353183 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact time gait-training feedback with home exercises (FBHE)
Number of subjects: 20
Study 36353183 — intervention group
Group type: COMPARATOR
Intervention: Home exercises (HE)
Number of subjects: 20
Study 32251036 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy-directed intervention in a randomized controlled trial for colorectal cancer screening.
Number of subjects: 0
Study 34897593 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhuang medicine medicated thread moxibustion (ZMTM) combined with Western medicines
Number of subjects: 241
Study 34897593 — intervention group
Group type: COMPARATOR
Intervention: Western medicines alone (pidotimod dispersible tablets, vitamin B compound tablets, compound cod liver oil‐zinc oxide ointment)
Number of subjects: 241
Study 34897593 — intervention group
Group type: EXPERIMENTAL
Intervention: ZMTM combined with Western medicines
Number of subjects: 241
Study 33217374 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft orthotics
Number of subjects: 44
Study 33217374 — intervention group
Group type: COMPARATOR
Intervention: Hard orthotics
Number of subjects: 44
Study 34967864 — intervention group
Group type: EXPERIMENTAL
Intervention: tSVF injection in the lateral 5 cm of the horizontal scar of 1 breast
Number of subjects: 40
Study 34967864 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection in the contralateral breast
Number of subjects: 40
Study 34191437 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted educational attainment
Number of subjects: 20926
Study 34191437 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating mono‐unsaturated fatty acid concentrations
Number of subjects: 20926
Study 34191437 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐reactive protein (CRP)
Number of subjects: 20926
Study 34191437 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐density lipoprotein (HDL)
Number of subjects: 20926
Study 34191437 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 20926
Study 34191437 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP)
Number of subjects: 20926
Study 35591203 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and coordination training with vibrotactile sensory augmentation (SA)
Number of subjects: 10
Study 35591203 — intervention group
Group type: COMPARATOR
Intervention: Balance and coordination training without vibrotactile sensory augmentation (SA)
Number of subjects: 10
Study 35591203 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and coordination training (both with and without SA)
Number of subjects: 10
Study 35591203 — intervention group
Group type: COMPARATOR
Intervention: Training with vibrotactile SA vs. without SA
Number of subjects: 10
Study 35591203 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (both with and without SA)
Number of subjects: 10
Study 616817652 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb rehabilitation robot training
Number of subjects: 60
Study 616817652 — intervention group
Group type: COMPARATOR
Intervention: Body weight support treadmill training (BWSTT)
Number of subjects: 60
Study 35642571 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model including age, marriage, grade, surgery, and tumor size
Number of subjects: 423
Study 33674242 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal voice intervention (recorded maternal voice before, during, and after venipuncture)
Number of subjects: 116
Study 33674242 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 116
Study 35190584 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attitude towards physical activity (PA)
Number of subjects: 68
Study 35190584 — intervention group
Group type: EXPERIMENTAL
Intervention: Other predictors (not specified)
Number of subjects: 68
Study 34493431 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-115 200 mg/d
Number of subjects: 50
Study 34493431 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-115 300 mg/d
Number of subjects: 50
Study 34493431 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-115 400 mg/d
Number of subjects: 50
Study 34493431 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-115 600 mg/d
Number of subjects: 50
Study 34493431 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 36394838 — intervention group
Group type: EXPERIMENTAL
Intervention: DCVax-L plus SOC temozolomide
Number of subjects: 331
Study 36394838 — intervention group
Group type: EXPERIMENTAL
Intervention: DCVax-L
Number of subjects: 331
Study 36394838 — intervention group
Group type: EXPERIMENTAL
Intervention: DCVax-L in patients with methylated MGMT
Number of subjects: 331
Study 34430972 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice/day plus aspirin 100 mg/day
Number of subjects: 1330
Study 32938935 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF, 8 h day−1)
Number of subjects: 11
Study 32938935 — intervention group
Group type: COMPARATOR
Intervention: Extended feeding (EXF, 15 h day−1)
Number of subjects: 11
Study 35998487 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire version with happiness question before categorical question
Number of subjects: 0
Study 35998487 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire version with happiness question after categorical question
Number of subjects: 0
Study 33965626 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of antenatal corticosteroids (ACS)
Number of subjects: 0
Study 33965626 — intervention group
Group type: COMPARATOR
Intervention: Single dose of antenatal corticosteroids (ACS)
Number of subjects: 0
Study 33965626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32852426 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-L-lactic acid (PLLA)
Number of subjects: 20
Study 32852426 — intervention group
Group type: COMPARATOR
Intervention: Bacteriostatic water (placebo)
Number of subjects: 20
Study 34672833 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping group
Number of subjects: 100
Study 34672833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy group
Number of subjects: 100
Study 34672833 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 34672833 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study 33007993 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotics project activities including four robotics workshops and one extended pilot session.
Number of subjects: 45
Study 33007993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 45
Study 34347093 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCon PTH 15, 18, or 21 µg PTH(1‐34)/day
Number of subjects: 59
Study 34347093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 33992298 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-density foam roller
Number of subjects: 10
Study 33992298 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard-density foam roller
Number of subjects: 10
Study 33992298 — intervention group
Group type: COMPARATOR
Intervention: Contralateral leg (control)
Number of subjects: 10
Study 36345115 — intervention group
Group type: EXPERIMENTAL
Intervention: IPR + EER group
Number of subjects: 81
Study 36345115 — intervention group
Group type: COMPARATOR
Intervention: IPR group
Number of subjects: 81
Study 32880992 — intervention group
Group type: EXPERIMENTAL
Intervention: NPEV positive by RT‐PCR
Number of subjects: 2519
Study 32880992 — intervention group
Group type: EXPERIMENTAL
Intervention: NPEV group
Number of subjects: 2519
Study 32880992 — intervention group
Group type: COMPARATOR
Intervention: Clinical and laboratory findings
Number of subjects: 2519
Study 32880992 — intervention group
Group type: COMPARATOR
Intervention: Adult patients
Number of subjects: 2519
Study 32880992 — intervention group
Group type: EXPERIMENTAL
Intervention: NPEV positive samples
Number of subjects: 2519
Study 36215414 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 μg/kg ideal bodyweight
Number of subjects: 87
Study 36215414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 33350678 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy (37% of patients received this treatment)
Number of subjects: 136
Study 33350678 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 136
Study 33350678 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent second-line therapy
Number of subjects: 136
Study 33350678 — intervention group
Group type: COMPARATOR
Intervention: Control group (no second-line therapy)
Number of subjects: 136
Study 32466446 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (MCEP)
Number of subjects: 64
Study 32466446 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 33594819 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose-derived regenerative cells (ADRCs) and lipotransfer to the axillary region
Number of subjects: 10
Study 32069353 — intervention group
Group type: EXPERIMENTAL
Intervention: pGCD59 ELISA
Number of subjects: 693
Study 33910604 — intervention group
Group type: EXPERIMENTAL
Intervention: IOERT
Number of subjects: 0
Study 33910604 — intervention group
Group type: COMPARATOR
Intervention: External beam electrons
Number of subjects: 0
Study 35484607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 66
Study 35484607 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 µg twice daily
Number of subjects: 66
Study 35484607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin-exenatide
Number of subjects: 66
Study 35484607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 32145088 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy
Number of subjects: 24
Study 33810451 — intervention group
Group type: EXPERIMENTAL
Intervention: >Your< Iron Syrup
Number of subjects: 94
Study 33810451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 32826114 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS ± HIPEC
Number of subjects: 0
Study 32826114 — intervention group
Group type: COMPARATOR
Intervention: Preemptive use of fresh frozen plasma
Number of subjects: 0
Study 35426830 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 2.5 mg/kg administered as a one-time targeted intra-arterial infusion after blood-brain barrier disruption (BBBD)
Number of subjects: 10
Study 32696185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic model-based simulation session
Number of subjects: 28
Study 32696185 — intervention group
Group type: COMPARATOR
Intervention: Lecture on SSLF procedure and anatomy
Number of subjects: 28
Study 32559474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg per day
Number of subjects: 53
Study 32559474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 34473652 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) in addition to standard of care (SOC)
Number of subjects: 350
Study 34473652 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 350
Study 32517482 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP insertion before PCI
Number of subjects: 275
Study 32517482 — intervention group
Group type: COMPARATOR
Intervention: IABP insertion after PCI
Number of subjects: 275
Study 35264106 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal radial artery (dRA) catheterization
Number of subjects: 161
Study 35264106 — intervention group
Group type: COMPARATOR
Intervention: Forearm radial artery (RA) catheterization
Number of subjects: 161
Study 33315247 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental contrasting with implementation intentions (MCII)
Number of subjects: 58
Study 33315247 — intervention group
Group type: COMPARATOR
Intervention: Stress management training
Number of subjects: 58
Study 35710491 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing Stigma among Healthcare Providers (RESHAPE) training with facilitation by people with lived experience of mental illness (PWLE) and caregivers using PhotoVoice.
Number of subjects: 216
Study 35710491 — intervention group
Group type: COMPARATOR
Intervention: Implementation-as-usual training on the World Health Organization Mental Health Gap Action Program Intervention Guide (mhGAP-IG) conducted by mental health specialists.
Number of subjects: 216
Study 35710491 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (RESHAPE and implementation-as-usual) will evaluate reach as the accuracy of detection of mental illness in primary care facilities determined by psychiatrists at 3 months after PCPs diagnose the patients.
Number of subjects: 216
Study 35710491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness and other RE-AIM outcomes will be assessed in both arms.
Number of subjects: 216
Study 32688045 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Training Technique (ATT)
Number of subjects: 89
Study 32688045 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CON)
Number of subjects: 89
Study 35411147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutamine (0.5 g/kg of 20% glutamine solution diluted with 0.9% NaCl up to 500 mL over 24 hours)
Number of subjects: 60
Study 35411147 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% NaCl over 24 hours)
Number of subjects: 60
Study 34622183 — intervention group
Group type: EXPERIMENTAL
Intervention: Inroads program (psychologist-supported, web-based cognitive behavioral therapy)
Number of subjects: 123
Study 34622183 — intervention group
Group type: EXPERIMENTAL
Intervention: Inroads program
Number of subjects: 123
Study 34622183 — intervention group
Group type: COMPARATOR
Intervention: Control (assessment plus alcohol information)
Number of subjects: 123
Study 32627438 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (110% motor threshold, 10 Hz, 20 minutes, three times a week for 4 weeks)
Number of subjects: 14
Study 34406354 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (aerobic exercise 3 times per week at 70% to 85% heart rate reserve for 12 weeks)
Number of subjects: 128
Study 34406354 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (up to 20 mg per day for 12 weeks)
Number of subjects: 128
Study 34406354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 34406354 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 128
Study 34406354 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and Escitalopram
Number of subjects: 128
Study 34406354 — intervention group
Group type: COMPARATOR
Intervention: Exercise, Escitalopram, and Placebo
Number of subjects: 128
Study 33206776 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Ultrasonic Irrigation (PUI)
Number of subjects: 80
Study 33206776 — intervention group
Group type: COMPARATOR
Intervention: Conventional Syringe Irrigation (CSI)
Number of subjects: 80
Study 33206776 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDesign Logic 25.06
Number of subjects: 80
Study 33206776 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDesign R 25.06
Number of subjects: 80
Study 33206776 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDesign Logic 35.05 with CSI
Number of subjects: 80
Study 33206776 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDesign R 35.05 with CSI
Number of subjects: 80
Study 33206776 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDesign Logic 35.05 with PUI
Number of subjects: 80
Study 33206776 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDesign R 35.05 with PUI
Number of subjects: 80
Study 36289464 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle intervention
Number of subjects: 219